Press releases
2025-04-24 08:00
Lipum AB – interim report Q1 for the period January-March 2025
Lipum AB (publ) has published the interim report Q1 for the period January-March 2025. Below is a summary, a complete report (only in Swedish) is available...
2025-04-11 11:28
Lipum Announces Successful Completion of Phase I Trial for SOL-116 - Supporting Continued Clinical Development
Lipum AB (publ) announces the completion and publication of the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116...
2025-04-07 13:00
Lipum AB (publ) has decided to postpone the Annual General Meeting for the financial year 2024 to June 16, 2025
The previous date for the Annual General Meeting for the financial year 2024 was May 14, 2025, but is now postponed to June 16, 2025. ContactsOla Sandborgh...
2025-02-26 08:30
Lipum AB – Year-end report 2024
Lipum AB (publ) has published the Q4 interim and year-end report for 2024. Below is a summary, a complete report (only in Swedish) is available on the...
2025-02-25 10:07
Lipum has successfully completed the phase I study with SOL-116
Lipum AB (publ) announces the completion of its phase I clinical trial (LPM-116-001) evaluating SOL-116, with positive results. The study confirmed SOL-116’s...
2024-12-17 14:08
Lipum and Age Labs have been granted funding from Eurostars
Lipum AB (publ) announces that the company, together with the Norwegian company Age Labs AS, has received a grant from Eurostars. The companies will establish...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual...
2024-11-18 10:00
Lipum Presents Promising Data on Novel Antibody SOL-116 at ACR 2024
Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from...
2024-10-25 08:00
Lipum AB – interim report Q3 for the period July-September 2024
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available...
2024-09-20 09:00
Lipum reports that the last patient has been enrolled in the ongoing phase 1 study with SOL-116
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in...